Overexpression of SNORA21 suppresses tumorgenesis of gallbladder cancer in vitro and in vivo

Qin, Yiyu; Yang, Zhou; Ge, Anxing; Chang, Li-Chung; Shi, Haiyan; Fu, Yang; Luo, Qiong

doi:10.1016/j.biopha.2019.109266

Cited by 10 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, not much is known about DEGs in gallbladder cancer walls. Unlike other studies, the present study used microarray analysis to identify DEGs for gallbladder cancer and gallbladder adenoma, whereas a precancerous lesion of gallbladder cancer was used as the control ( 35 , 39 – 41 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer

Zhu

Li²,

Niu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Gallbladder cancer is the most common biliary tract malignant tumor, with unfavorable patient outcomes. The present study aimed to identify potential diagnostic or prognostic biomarkers for gallbladder cancer. To do so, differentially expressed genes in the gallbladder walls and tumor tissues of patients with gallbladder cancer were analyzed via microarray. Furthermore, a protein-protein interaction network was constructed and genes with a degree score >10 were selected as hub genes. As ubiquitin conjugating enzyme E2T (UBE2T) was considered to be a hub gene, its expression was assessed via reverse transcription-quantitative (RT-q)PCR and immunohistochemistry (IHC). In addition, the association between UBE2T expression and the clinicopathological characteristics of patients with gallbladder cancer was analyzed using the χ 2 test. Furthermore, all patients were divided into high-and low groups based on UBE2T expression level and overall survival analysis was performed. Univariate and multivariate Cox regression analyses were performed to determine whether UBE2T may serve as an independent risk factor for gallbladder cancer. The results demonstrated that UBE2T expression was upregulated in the gallbladder walls and tumor tissues of patients with gallbladder cancer. Furthermore, UBE2T expression level was confirmed to be upregulated following RT-qPCR, and results from IHC demonstrated that UBE2T was predominantly expressed in the cytoplasm of gallbladder cancer cells. In addition, high UBE2T expression level was associated with clinical stage, T classification, N classification and M classification. The results from Univariate and multivariate analyses indicated that UBE2T expression level may be considered as an independent risk factor for gallbladder cancer. Taken together, the findings from this study suggested that high UBE2T expression level may contribute to the poor prognosis of patients with gallbladder cancer, and that UBE2T may act as an independent prognostic biomarker for these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer

Zhu

Li²,

Niu

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…[28][29][30]. SNORA21 was demonstrated upregulated in gallbladder cancer [31], gastric cancer [32] and colorectal cancer [33], which is a predictor of poor survival of the latter two. Recently, more and more evidence has con rmed that overexpression of SNORA21 could inhibit the proliferation, migration and invasion and enhance apoptosis of gallbladder cancer cells.…”

Section: Discussionmentioning

confidence: 99%

U2AF2 Promote the Proliferation and Migration of Esophageal Adenocarcinoma Cells by Sustaining the Mrna Stability of SNORA21

Gao¹,

Chen²,

B³

2021

Preprint

View full text Add to dashboard Cite

Background Esophageal adenocarcinoma has gains predominance with squamous carcinoma moving to a second place in the western world. The 5-year survival rate of patients with esophageal cancer (EC) is still between 15–25%, although the treatment strategies for EC have been improved. RNA-binding proteins (RBPs) are key players in post-transcriptional events. Particularly, the U2 snRNP auxiliary (U2AF2), as a canonical RBP, has been reported to play an important role in the development, progression, and metastasis of several human cancers. However, the biological role of U2AF2 in the context of malignancies, including EC, has not yet been reported. This study is aimed to investigate the role and mechanism of U2AF2 in esophageal adenocarcinoma cell line. Methods The expression level of U2AF2 and SNORA21 was analysed by TCGA database. The expression level of U2AF2 and SNORA21 in esophageal adenocarcinoma cells was determined by Western Blot and RT-qPCR assay. The cell viability and proliferation was detected by CCK8 assay and BrdU incorporation assay. The apoptosis was examined by caspase3 immunocytofluorescense. The protein levels of Bax, Bcl-2 and E-cadherin were explored by Western Blot assay. The interaction between U2AF2 and SNORA21 was predicted by Starbase 3.0 and confirmed by RIP assay. The RNA regulated by U2AF2 was through RNA-seq analysis on the basis of downregulation of U2AF2. Results The expression of U2AF2 and SNORA21 was found to be upregulated and served as an unfavourable factor which negatively related with overall survival of esophageal adenocarcinoma patients. Silencing the expression of U2AF2 or SNORA21 could suppress the proliferation and migration of OE19 and OE33 cells and stimulate its apoptosis. Moreover, we identified that the U2AF2 could bind and interact with SNORA21 to sustain its stability. Furthermore, we show that overexpression of SNORA21 could rescue the proliferation inhibition phenotype caused by si-U2AF2. Conclusion Our study provides several lines of evidence supporting the intriguing concept that U2AF2 could promote the proliferation of OE19 and OE33 cells by directly targeting SNORA21, which might serve as a novel candidate biomarker and a new target for the treatment of esophageal adenocarcinoma.

show abstract

“…Nevertheless, some ncRNAs, such as promoter-associated transcripts (PATs), enhancer RNAs (eRNAs), and circRNAs, vary in length and thus can simultaneously be classified under sncRNAs and lncRNA [ 17 , 18 , 19 , 20 ]. Several studies have demonstrated the close association of different regulatory ncRNAs such as circRNAs, lncRNAs, miRNAs, and snoRNAs in the initiation and progression of GBC ( Figure 1 ) [ 21 , 22 , 23 , 24 ].…”

Section: Noncoding Rnas (Ncrnas) In Gbcmentioning

confidence: 99%

“…Recent studies have reported the role of snoRNAs in regulating GBC both in vitro and in vivo. Additionally, several studies have reported their role as oncogenes and tumor suppressors in GBC [ 21 , 51 ].…”

Section: Noncoding Rnas (Ncrnas) In Gbcmentioning

confidence: 99%

“…The ncRNAs have emerged as important regulators of critical signaling pathways and prognostic markers in several cancers, including GBC ( Figure 2 ). Accumulating evidence has demonstrated that lncRNAs play a significant regulatory role in GBC tumorigenesis ( Table 1 ) [ 21 , 22 , 23 , 24 , 26 , 28 , 36 , 37 , 47 , 48 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , ...…”

Section: Deregulation Of Ncrnas In Different Signaling Pathwaysmentioning

confidence: 99%

See 1 more Smart Citation

Reiterating the Emergence of Noncoding RNAs as Regulators of the Critical Hallmarks of Gall Bladder Cancer

et al. 2021

View full text Add to dashboard Cite

Gall bladder cancer (GBC) is a rare and one of the most aggressive types of malignancies, often associated with a poor prognosis and survival. It is a highly metastatic cancer and is often not diagnosed at the initial stages, which contributes to a poor survival rate of patients. The poor diagnosis and chemoresistance associated with the disease limit the scope of the currently available surgical and nonsurgical treatment modalities. Thus, there is a need to explore novel therapeutic targets and biomarkers that will help relieve the severity of the disease and lead to advanced therapeutic strategies. Accumulating evidence has correlated the atypical expression of various noncoding RNAs (ncRNAs), including circular RNAs (circRNAs), long noncoding RNAs (lncRNAs), microRNAs (miRNAs), and small nucleolar RNAs (snoRNA) with the increased cell proliferation, epithelial–mesenchymal transition (EMT), invasion, migration, metastasis, chemoresistance, and decreased apoptosis in GBC. Numerous reports have indicated that the dysregulated expression of ncRNAs is associated with poor prognosis and lower disease-free and overall survival in GBC patients. These reports suggest that ncRNAs might be considered novel diagnostic and prognostic markers for the management of GBC. The present review recapitulates the association of various ncRNAs in the initiation and progression of GBC and the development of novel therapeutic strategies by exploring their functional and regulatory role.

show abstract

Overexpression of SNORA21 suppresses tumorgenesis of gallbladder cancer in vitro and in vivo

Cited by 10 publications

References 26 publications

Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer

Identification of UBE2T as an independent prognostic biomarker for gallbladder cancer

U2AF2 Promote the Proliferation and Migration of Esophageal Adenocarcinoma Cells by Sustaining the Mrna Stability of SNORA21

Reiterating the Emergence of Noncoding RNAs as Regulators of the Critical Hallmarks of Gall Bladder Cancer

Contact Info

Product

Resources

About